Efficacy and safety of splenetomy on telaprevir-based triple therapy in chronic hepatitis C patients with thrombocytopenia

Efficacy and safety of splenetomy on telaprevir-based triple therapy in chronic hepatitis C patients with thrombocytopenia - Efficacy and safety of splenetomy on triple therapy in chronic hepatitis C patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012291

Enrollment

Registered

2013-11-14

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C patients with splenectomy

Exclusion criteria

Exclusion criteria: Hepatic decompensation, excessive active alcohol consumption, the presence of active cancer at entry

Design outcomes

Primary

Measure	Time frame
Sustained virological response	—

Secondary

Measure	Time frame
Treatment discontinuation and adherence	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

Kyushu University Hospital Department of General Internal Medicine

eogawa@gim.med.kyushu-u.ac.jp+81-92-642-5909

Outcome results